Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies.

Hewitt NJ, Lechón MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, Guillouzo A, Tuschl G, Li AP, LeCluyse E, Groothuis GM, Hengstler JG.

Drug Metab Rev. 2007;39(1):159-234. Review.

PMID:
17364884
2.

HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro.

Lübberstedt M, Müller-Vieira U, Mayer M, Biemel KM, Knöspel F, Knobeloch D, Nüssler AK, Gerlach JC, Zeilinger K.

J Pharmacol Toxicol Methods. 2011 Jan-Feb;63(1):59-68. doi: 10.1016/j.vascn.2010.04.013. Epub 2010 May 9.

PMID:
20460162
3.
4.

The pivotal role of hepatocytes in drug discovery.

Soars MG, McGinnity DF, Grime K, Riley RJ.

Chem Biol Interact. 2007 May 20;168(1):2-15. Epub 2006 Nov 18. Review.

PMID:
17208208
5.

Hepatocytes as a tool in drug metabolism, transport and safety evaluations in drug discovery.

Sahi J, Grepper S, Smith C.

Curr Drug Discov Technol. 2010 Sep;7(3):188-98. Review.

PMID:
20843293
6.

Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design.

Di L, Keefer C, Scott DO, Strelevitz TJ, Chang G, Bi YA, Lai Y, Duckworth J, Fenner K, Troutman MD, Obach RS.

Eur J Med Chem. 2012 Nov;57:441-8. doi: 10.1016/j.ejmech.2012.06.043. Epub 2012 Jul 16.

PMID:
22840492
7.

Human hepatocytes as a tool for studying toxicity and drug metabolism.

Gómez-Lechón MJ, Donato MT, Castell JV, Jover R.

Curr Drug Metab. 2003 Aug;4(4):292-312. Review.

PMID:
12871046
8.

Prediction of in vivo rat biliary drug clearance from an in vitro hepatocyte efflux model.

Lundquist P, Lööf J, Fagerholm U, Sjögren I, Johansson J, Briem S, Hoogstraate J, Afzelius L, Andersson TB.

Drug Metab Dispos. 2014 Mar;42(3):459-68. doi: 10.1124/dmd.113.054155. Epub 2014 Jan 6.

9.

Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations.

Hewitt NJ, Lecluyse EL, Ferguson SS.

Xenobiotica. 2007 Oct-Nov;37(10-11):1196-224. Review.

PMID:
17968743
10.

Role of human hepatocyte nuclear factor 4alpha in the expression of drug-metabolizing enzymes and transporters in human hepatocytes assessed by use of small interfering RNA.

Kamiyama Y, Matsubara T, Yoshinari K, Nagata K, Kamimura H, Yamazoe Y.

Drug Metab Pharmacokinet. 2007 Aug;22(4):287-98.

11.

Human hepatocytes in primary culture: the choice to investigate drug metabolism in man.

Gómez-Lechón MJ, Donato MT, Castell JV, Jover R.

Curr Drug Metab. 2004 Oct;5(5):443-62. Review.

PMID:
15544436
12.

The use of human hepatocytes to investigate drug metabolism and CYP enzyme induction.

Klieber S, Torreilles F, Guillou F, Fabre G.

Methods Mol Biol. 2010;640:295-308. doi: 10.1007/978-1-60761-688-7_16.

PMID:
20645059
13.

Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins.

Gerets HH, Tilmant K, Gerin B, Chanteux H, Depelchin BO, Dhalluin S, Atienzar FA.

Cell Biol Toxicol. 2012 Apr;28(2):69-87. doi: 10.1007/s10565-011-9208-4. Epub 2012 Jan 19.

14.

An update on metabolism studies using human hepatocytes in primary culture.

Gómez-Lechón MJ, Castell JV, Donato MT.

Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):837-54. doi: 10.1517/17425255.4.7.837 . Review.

PMID:
18624674
15.

Metabolic characterization of primary rat hepatocytes cultivated in parallel microfluidic biochips.

Legendre A, Baudoin R, Alberto G, Paullier P, Naudot M, Bricks T, Brocheton J, Jacques S, Cotton J, Leclerc E.

J Pharm Sci. 2013 Sep;102(9):3264-76. doi: 10.1002/jps.23466. Epub 2013 Feb 19.

PMID:
23423727
16.

A novel matrix for the short-term storage of cells: utility in drug metabolism and drug transporter studies with rat, dog and human hepatocytes.

Palmgren AP, Fihn BM, Bird J, Courtney P, Grime K.

Xenobiotica. 2013 Jun;43(6):487-97. doi: 10.3109/00498254.2012.738316. Epub 2012 Nov 9.

PMID:
23137276
17.

Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction.

Bauman JN, Kelly JM, Tripathy S, Zhao SX, Lam WW, Kalgutkar AS, Obach RS.

Chem Res Toxicol. 2009 Feb;22(2):332-40. doi: 10.1021/tx800407w.

PMID:
19161298
18.

Hepatocytes--the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo.

Gómez-Lechón MJ, Castell JV, Donato MT.

Chem Biol Interact. 2007 May 20;168(1):30-50. Epub 2006 Nov 28. Review.

PMID:
17134688
19.

A novel relay method for determining low-clearance values.

Di L, Trapa P, Obach RS, Atkinson K, Bi YA, Wolford AC, Tan B, McDonald TS, Lai Y, Tremaine LM.

Drug Metab Dispos. 2012 Sep;40(9):1860-5. doi: 10.1124/dmd.112.046425. Epub 2012 May 29.

20.

Prediction of Metabolic Clearance for Low-Turnover Compounds Using Plated Hepatocytes with Enzyme Activity Correction.

Ma B, Eisenhandler R, Kuo Y, Rearden P, Li Y, Manley PJ, Smith S, Menzel K.

Eur J Drug Metab Pharmacokinet. 2017 Apr;42(2):319-326. doi: 10.1007/s13318-016-0336-3.

PMID:
27101423

Supplemental Content

Support Center